EP3589646A4 - Cd19-zusammensetzungen und verfahren für die immuntherapie - Google Patents
Cd19-zusammensetzungen und verfahren für die immuntherapie Download PDFInfo
- Publication number
- EP3589646A4 EP3589646A4 EP18760420.2A EP18760420A EP3589646A4 EP 3589646 A4 EP3589646 A4 EP 3589646A4 EP 18760420 A EP18760420 A EP 18760420A EP 3589646 A4 EP3589646 A4 EP 3589646A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- immunotherapy
- compositions
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000009169 immunotherapy Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/208—IL-12
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2086—IL-13 to IL-16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3061—Blood cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
- C12N9/0026—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5)
- C12N9/0028—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on CH-NH groups of donors (1.5) with NAD or NADP as acceptor (1.5.1)
- C12N9/003—Dihydrofolate reductase [DHFR] (1.5.1.3)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/90—Isomerases (5.)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/49—Breast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/57—Skin; melanoma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Urology & Nephrology (AREA)
- Marine Sciences & Fisheries (AREA)
- Pathology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762466601P | 2017-03-03 | 2017-03-03 | |
US201762484052P | 2017-04-11 | 2017-04-11 | |
PCT/US2018/020741 WO2018161017A1 (en) | 2017-03-03 | 2018-03-02 | Cd19 compositions and methods for immunotherapy |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3589646A1 EP3589646A1 (de) | 2020-01-08 |
EP3589646A4 true EP3589646A4 (de) | 2021-01-20 |
Family
ID=63371272
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP18760420.2A Pending EP3589646A4 (de) | 2017-03-03 | 2018-03-02 | Cd19-zusammensetzungen und verfahren für die immuntherapie |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP3589646A4 (de) |
JP (2) | JP7341900B2 (de) |
KR (1) | KR20200010181A (de) |
CN (1) | CN110831961B (de) |
AU (2) | AU2018227583B2 (de) |
CA (1) | CA3055202A1 (de) |
SG (2) | SG10202001869VA (de) |
WO (1) | WO2018161017A1 (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10704021B2 (en) | 2012-03-15 | 2020-07-07 | Flodesign Sonics, Inc. | Acoustic perfusion devices |
WO2015105955A1 (en) | 2014-01-08 | 2015-07-16 | Flodesign Sonics, Inc. | Acoustophoresis device with dual acoustophoretic chamber |
US11377651B2 (en) | 2016-10-19 | 2022-07-05 | Flodesign Sonics, Inc. | Cell therapy processes utilizing acoustophoresis |
US11708572B2 (en) | 2015-04-29 | 2023-07-25 | Flodesign Sonics, Inc. | Acoustic cell separation techniques and processes |
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
MA49403A (fr) | 2017-06-12 | 2021-03-24 | Obsidian Therapeutics Inc | Compositions de pde5 et méthodes d'immunothérapie |
WO2019118921A1 (en) | 2017-12-14 | 2019-06-20 | Flodesign Sonics, Inc. | Acoustic transducer drive and controller |
CA3085781A1 (en) | 2017-12-15 | 2019-06-20 | Aleta Biotherapeutics Inc. | Cd19 variants |
JP7536649B2 (ja) * | 2018-11-06 | 2024-08-20 | イミュニティーバイオ、インコーポレイテッド | キメラ抗原受容体で修飾されたnk-92細胞 |
AU2019377115A1 (en) * | 2018-11-07 | 2021-05-20 | Akouos, Inc. | Use of adeno-associated viral vectors to correct gene defects/ express proteins in hair cells and supporting cells in the inner ear |
EP3894011A1 (de) * | 2018-12-11 | 2021-10-20 | Obsidian Therapeutics, Inc. | Membrangebundene il12-zusammensetzungen und verfahren zur abstimmbaren regulierung |
EP3893899A2 (de) | 2018-12-12 | 2021-10-20 | Kite Pharma, Inc. | Chimäre antigen-rezeptoren und car-t-zellen und verwendungsverfahren |
CN116479022A (zh) * | 2018-12-12 | 2023-07-25 | 中南大学 | 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用 |
WO2020156335A1 (zh) * | 2019-01-29 | 2020-08-06 | 上海交通大学 | 一种嵌合抗原受体及其应用 |
WO2020172643A2 (en) * | 2019-02-21 | 2020-08-27 | Luk John M | Artificial immunosurveillance chimeric antigen receptor (ai-car) and cells expressing the same |
CN113811549A (zh) | 2019-02-21 | 2021-12-17 | Xencor股份有限公司 | 非靶向和靶向性il-10 fc融合蛋白 |
WO2020177992A1 (en) | 2019-03-01 | 2020-09-10 | Universität Für Bodenkultur Wien | Stabilized extracellular domain of cd19 |
KR20210137085A (ko) * | 2019-03-05 | 2021-11-17 | 엔카르타, 인크. | Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도 |
AU2020235865A1 (en) * | 2019-03-08 | 2021-09-23 | Obsidian Therapeutics, Inc. | Human carbonic anhydrase 2 compositions and methods for tunable regulation |
EP3935077A1 (de) * | 2019-03-08 | 2022-01-12 | Obsidian Therapeutics, Inc. | Cd40l-zusammensetzungen und verfahren zur abstimmbaren regulierung |
CA3134308A1 (en) * | 2019-04-26 | 2020-10-29 | Thomas Charles PERTEL | Rituximab-resistant chimeric antigen receptors and uses thereof |
CN110079504A (zh) * | 2019-05-06 | 2019-08-02 | 山东大学第二医院 | 一种含有不稳定结构域的car-t细胞及其制备方法和调节car-t细胞功能方法 |
CN110075275B (zh) * | 2019-05-15 | 2023-03-24 | 苏州大学 | IL-36β的应用 |
AU2020290522A1 (en) * | 2019-06-12 | 2022-01-20 | Obsidian Therapeutics, Inc. | CA2 compositions and methods for tunable regulation |
CN110818803B (zh) * | 2019-07-24 | 2023-01-03 | 浙江启新生物技术有限公司 | 分泌表达il15ra-il15融合蛋白、ccl21趋化因子的嵌合抗原受体-t细胞及应用 |
US20220289843A1 (en) * | 2019-08-19 | 2022-09-15 | Elpis Biopharmaceuticals | Anti-cd19 antibodies and uses thereof |
EP4021464A4 (de) * | 2019-08-27 | 2024-01-03 | The Trustees of The University of Pennsylvania | Synthetische cars zur behandlung von il13ra2-positiven tumoren bei menschen und hunden |
US20230092895A1 (en) | 2019-08-30 | 2023-03-23 | Obsidian Therapeutics, Inc. | Tandem cd19 car-based compositions and methods for immunotherapy |
WO2021046451A1 (en) * | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
CN114651003A (zh) | 2019-09-10 | 2022-06-21 | 黑曜石疗法公司 | 用于可调调节的ca2-il15融合蛋白 |
US11896619B2 (en) * | 2020-03-10 | 2024-02-13 | Massachusetts Institute Of Technology | Compositions and methods for immunotherapy of NPM1c-positive cancer |
CN116568805A (zh) * | 2020-09-02 | 2023-08-08 | 恩卡尔塔公司 | 工程化自然杀伤细胞的增强扩增和细胞毒性及其用途 |
CN116018402A (zh) * | 2020-09-04 | 2023-04-25 | 心脏康复株式会社 | iPS细胞的品质改善剂、iPS细胞的制备方法、iPS细胞、及iPS细胞制备用组合物 |
WO2022109443A1 (en) * | 2020-11-23 | 2022-05-27 | The Regents Of The University Of Michigan | Single-chain antibody against flavivirus ns1 protein |
CN112795543B (zh) * | 2021-02-04 | 2022-09-27 | 华中农业大学 | 杂交瘤细胞株及其分泌的抗草鱼IL-15Rα单克隆抗体和应用 |
CN113403274B (zh) * | 2021-06-28 | 2023-11-10 | 上海睿臻迈生物医疗科技有限公司 | 细胞治疗组合物及其制备方法和作为过敏性反应及自身免疫疾病治疗药物的应用 |
CN113736810B (zh) * | 2021-09-08 | 2024-05-24 | 苏州因特药物研发有限公司 | 构建体、载体、蛋白、细胞、制备方法、产品及应用 |
CN114129718B (zh) * | 2021-10-19 | 2024-05-03 | 华东师范大学 | 一种用于体内自组装car-t的纳米递送系统及其制备方法和应用 |
CN114558126A (zh) * | 2021-11-04 | 2022-05-31 | 苏州大学附属第一医院 | 序贯输注cd19 car-t和bcma car-t细胞在急性白血病患者免疫介导血小板输注无效中的联合应用 |
CN116789822A (zh) * | 2022-03-18 | 2023-09-22 | 广东东阳光药业股份有限公司 | Claudin18.2人源化抗体及其应用 |
CN116516007B (zh) * | 2023-04-18 | 2024-01-19 | 华中科技大学同济医学院附属协和医院 | Cd19表达的检测方法 |
CN116536375B (zh) * | 2023-06-28 | 2023-11-10 | 北京大学深圳研究生院 | merocyclophanes类化合物的化学-酶法合成方法及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8173792B2 (en) * | 2007-02-09 | 2012-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells using synthetic small molecules |
US20140010791A1 (en) * | 2008-05-07 | 2014-01-09 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for regulating protein function in cells in vivo using synthetic small molecules |
WO2018231759A1 (en) * | 2017-06-12 | 2018-12-20 | Obsidian Therapeutics, Inc. | Pde5 compositions and methods for immunotherapy |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005012493A2 (en) * | 2003-07-31 | 2005-02-10 | Immunomedics, Inc. | Anti-cd19 antibodies |
US20130266551A1 (en) * | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
KR100787393B1 (ko) * | 2006-03-23 | 2007-12-21 | 학교법인 한림대학교 | 세포 도입성 fk506 결합 단백질의 융합 단백질 |
SG190997A1 (en) * | 2010-12-09 | 2013-07-31 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
JP6267644B2 (ja) * | 2011-10-20 | 2018-01-24 | アメリカ合衆国 | 抗cd22キメラ抗原受容体 |
US9846162B2 (en) * | 2012-05-14 | 2017-12-19 | Yale University | Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer |
US9675633B2 (en) * | 2013-03-14 | 2017-06-13 | Board Of Regents, The University Of Texas System | miRNA for treating cancer and for use with adoptive immunotherapies |
AU2014265487B2 (en) * | 2013-05-14 | 2020-10-22 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (CAR) T-cells |
WO2015028574A1 (en) * | 2013-08-28 | 2015-03-05 | Pci Biotech As | Compound and method for vaccination and immunisation |
EP3057994B1 (de) * | 2013-10-15 | 2020-09-23 | The Scripps Research Institute | Chimäre peptidische antigenrezeptor-t-zell-schalter und verwendungen davon |
US11382963B2 (en) * | 2015-01-12 | 2022-07-12 | Pieris Pharmaceuticals Gmbh | Engineered T cells and uses therefor |
EP3259352A4 (de) * | 2015-02-19 | 2018-12-05 | University of Florida Research Foundation, Inc. | Chimäre antigenrezeptoren und verfahren zur verwendung davon |
EP3443001A4 (de) * | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | Regulierte bioschaltkreissysteme |
BR112019001570A2 (pt) * | 2016-07-28 | 2019-07-09 | Novartis Ag | terapias de combinação de receptores de antígeno quiméricos e inibidores de pd-1 |
-
2018
- 2018-03-02 KR KR1020197029002A patent/KR20200010181A/ko active Search and Examination
- 2018-03-02 AU AU2018227583A patent/AU2018227583B2/en active Active
- 2018-03-02 CA CA3055202A patent/CA3055202A1/en active Pending
- 2018-03-02 JP JP2019568594A patent/JP7341900B2/ja active Active
- 2018-03-02 CN CN201880025103.XA patent/CN110831961B/zh active Active
- 2018-03-02 SG SG10202001869VA patent/SG10202001869VA/en unknown
- 2018-03-02 SG SG11201907922PA patent/SG11201907922PA/en unknown
- 2018-03-02 EP EP18760420.2A patent/EP3589646A4/de active Pending
- 2018-03-02 WO PCT/US2018/020741 patent/WO2018161017A1/en unknown
-
2023
- 2023-08-11 AU AU2023214349A patent/AU2023214349A1/en active Pending
- 2023-08-30 JP JP2023139792A patent/JP2023164900A/ja active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8173792B2 (en) * | 2007-02-09 | 2012-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Method for regulating protein function in cells using synthetic small molecules |
US20140010791A1 (en) * | 2008-05-07 | 2014-01-09 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for regulating protein function in cells in vivo using synthetic small molecules |
WO2018231759A1 (en) * | 2017-06-12 | 2018-12-20 | Obsidian Therapeutics, Inc. | Pde5 compositions and methods for immunotherapy |
Non-Patent Citations (1)
Title |
---|
ALEXANDRE JUILLERAT ET AL: "Design of chimeric antigen receptors with integrated controllable transient functions", SCIENTIFIC REPORTS, vol. 6, 11 January 2016 (2016-01-11), pages 18950, XP055271820, DOI: 10.1038/srep18950 * |
Also Published As
Publication number | Publication date |
---|---|
AU2018227583A1 (en) | 2019-10-17 |
AU2018227583B2 (en) | 2023-06-01 |
JP2023164900A (ja) | 2023-11-14 |
JP2020511529A (ja) | 2020-04-16 |
AU2023214349A1 (en) | 2023-08-31 |
JP7341900B2 (ja) | 2023-09-11 |
SG11201907922PA (en) | 2019-09-27 |
CN110831961A (zh) | 2020-02-21 |
CA3055202A1 (en) | 2018-09-07 |
KR20200010181A (ko) | 2020-01-30 |
SG10202001869VA (en) | 2020-04-29 |
CN110831961B (zh) | 2024-01-02 |
EP3589646A1 (de) | 2020-01-08 |
WO2018161017A1 (en) | 2018-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3589646A4 (de) | Cd19-zusammensetzungen und verfahren für die immuntherapie | |
EP3589373A4 (de) | Zusammensetzungen und verfahren für die immuntherapie | |
EP3765608A4 (de) | Genregulatorische zusammensetzungen und verfahren für verbesserte immuntherapie | |
IL282225A (en) | Preparations and methods for immunotherapy | |
EP3765094A4 (de) | Genregulatorische zusammensetzungen und verfahren zur verbesserten immuntherapie | |
EP3493827A4 (de) | Zusammensetzungen und verfahren für die immuntherapie | |
EP3638289A4 (de) | Pde5-zusammensetzungen und verfahren zur immuntherapie | |
EP3823673A4 (de) | Anti-cd112r-zusammensetzungen und verfahren | |
EP3600325A4 (de) | Neuartige zusammensetzungen und verfahren | |
EP3242940A4 (de) | Verfahren und zusammensetzungen für kombinationsimmuntherapie | |
EP3286213A4 (de) | Verfahren und zusammensetzungen für eine kombinationsimmuntherapie | |
EP3402495A4 (de) | Verfahren und zusammensetzungen für t-zellimmuntherapie | |
EP3765092A4 (de) | Genregulatorische zusammensetzungen und verfahren für verbesserte immuntherapie | |
EP3092256A4 (de) | Verbindungen und zusammensetzungen für die immuntherapie | |
EP3316909A4 (de) | Anti-ntb-a-antikörper sowie zugehörige zusammensetzungen und verfahren | |
EP3273950A4 (de) | Adjuvanszusammensetzungen und zugehörige verfahren | |
EP3503879A4 (de) | Zusammensetzung und verfahren dafür | |
EP3436083A4 (de) | Neuartige zusammensetzungen und verfahren | |
EP3247408A4 (de) | Zusammensetzungen und verfahren für die krebsimmuntherapie | |
EP3442543A4 (de) | Zusammensetzungen und verfahren für neurogenese | |
EP3500262A4 (de) | Zusammensetzungen und verfahren für die krebsimmuntherapie | |
EP3706558A4 (de) | Zusammensetzungen und verfahren für aquakultur | |
IL283644A (en) | Preparations and methods for immunotherapy | |
EP3752194A4 (de) | Zusammensetzungen und verfahren für die tumorimmuntherapie | |
EP3709871A4 (de) | Zusammensetzungen und verfahren zur intensivierung visueller funktionen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20191001 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: BRISKIN, MICHAEL JOSEPH Inventor name: OLS, MICHELLE LYNN Inventor name: DOLINSKI, BRIAN Inventor name: SUN, DEXUE Inventor name: EZELL, TUCKER Inventor name: LI, DAN JUN Inventor name: KOSMIDER, NICOLE Inventor name: BALAKRISHNAN, VIJAYA Inventor name: SURI, VIPIN Inventor name: HELLER, SCOTT FRANCIS Inventor name: KULKARNI, ABHISHEK Inventor name: ELPEK, KUTLU GOKSU |
|
RAV | Requested validation state of the european patent: fee paid |
Extension state: MD Effective date: 20191001 |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20201218 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: C07K 14/55 20060101ALI20201214BHEP Ipc: C07K 14/705 20060101ALI20201214BHEP Ipc: C07K 16/30 20060101ALI20201214BHEP Ipc: A61K 31/505 20060101ALI20201214BHEP Ipc: C12N 9/64 20060101ALI20201214BHEP Ipc: A61K 35/00 20060101ALI20201214BHEP Ipc: A61K 31/519 20060101ALI20201214BHEP Ipc: C12N 9/02 20060101ALI20201214BHEP Ipc: C07K 14/54 20060101ALI20201214BHEP Ipc: A61P 37/02 20060101ALI20201214BHEP Ipc: A61K 38/00 20060101ALI20201214BHEP Ipc: C07K 14/725 20060101ALI20201214BHEP Ipc: C12N 15/62 20060101ALI20201214BHEP Ipc: A61P 35/00 20060101ALI20201214BHEP Ipc: A61K 39/00 20060101ALI20201214BHEP Ipc: C07K 16/28 20060101ALI20201214BHEP Ipc: A61K 39/39 20060101ALI20201214BHEP Ipc: A61K 35/14 20150101ALI20201214BHEP Ipc: C12N 9/06 20060101AFI20201214BHEP |